Interstitial granulomatous drug reaction associated with tyrosine kinase inhibitor dasatinib

Leukemia & lymphoma/Leukemia and lymphoma 2026

View at publisher
Authors: Grant J. Riew, Mihir K. Patil, Soo Hyun Kim, Alvaro C. Laga, Rahul S. Vedula, Connie R. Shi
DOI: 10.1080/10428194.2026.2653809
Cited by: 1
References: 5

Abstract

Dasatinib is a second-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia [1]. Dasati...

Fields of Study & Subjects

Sarcoidosis and Beryllium Toxicity Research Chronic Myeloid Leukemia Treatments Lung Cancer Treatments and Mutations

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Publisher
Informa UK Limited
Volume
67
Issue
8
Pages
1833–1835
Publication date
1 April 2026
Language
EN